Tag Archives: RVNC

Revance Therapeutics (RVNC) Received its Third Buy in a Row

After Needham and Stifel Nicolaus gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Revance Therapeutics today and set a price

Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (NASDAQ: RVNC) and Celgene (NASDAQ: CELG)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (RVNC – Research Report) and Celgene (CELG – Research Report). Revance Therapeutics (RVNC) In a report released today, Difei Yang from

Revance Therapeutics (RVNC) Receives a Buy from Mizuho Securities

Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $34.00. The company’s shares closed last Monday at $12.70, close to its 52-week low of $9.88. According

Mizuho Securities Thinks Revance Therapeutics’ Stock is Going to Recover

Mizuho Securities analyst Difei Yang maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) yesterday and set a price target of $37. The company’s shares closed yesterday at $13.59, close to its 52-week low of $12.87. Yang said:

Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (NASDAQ: RVNC) and Tandem Diabetes Care Inc (NASDAQ: TNDM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revance Therapeutics (RVNC – Research Report) and Tandem Diabetes Care Inc (TNDM – Research Report) with bullish sentiments. Revance Therapeutics (RVNC) Mizuho

H.C. Wainwright Initiates a Buy Rating on Revance Therapeutics (RVNC)

In a report released today, Douglas Tsao from H.C. Wainwright initiated coverage with a Buy rating on Revance Therapeutics (RVNC – Research Report) and a price target of $25. The company’s shares closed yesterday at $17.78, close to its 52-week